TY - CONF
TI - Four-year follow-up of the phase 3 POLLUX study of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in relapsed or refractory multiple myeloma
AU - Cook, G
AU - Kaufman, JL
AU - Usmani, SZ
AU - San-Miguel, J
AU - Bahlis, NJ
AU - White, D
AU - Benboubker, L
AU - Leiba, M
AU - Ho, PJ
AU - Kim, K
AU - others
PY - 2020
SP - 20--20
PB - 
T2 - BRITISH JOURNAL OF HAEMATOLOGY
TODO - null
TODO - null
TODO - null
ER -